Anaplastic lymphoma kinase (ALK) inhibitors have shown significant efficacy in ﻿ALK -rearranged non-small cell lung cancer (NSCLC) patients with good performance status (PS) in multiple randomised studies. This evidence concerns the gene ALK and non-small cell lung carcinoma.